PanTera is a Belgian joint venture established by Ion Beam Applications (IBA) and the Belgian Nuclear Research Centre (SCK CEN). The company focuses on the production and supply of actinium-225 (225Ac), an alpha-emitting radioisotope used in targeted radiopharmaceutical therapies. Operating from the European Union, PanTera aims to strengthen regional and global access to medical isotopes critical for oncology research and treatment.
PanTera’s activities span isotope production, radiochemical processing, and quality-controlled packaging and logistics geared to support preclinical studies, clinical trials, and eventual commercial use. The company is developing scalable, GMP-compliant capacity to meet growing demand for 225Ac, a strategic input for targeted alpha therapy. Through the combined nuclear and accelerator expertise of its founding organizations, PanTera contributes to building a reliable supply chain for advanced radiopharmaceuticals.
